NASDAQ: NGNENeurogene Inc Stock
$32.03+1.62 (+5.33%)
Updated Jun 26, 2026
NGNE Price
$32.03
Fair Value Price
$4.44
Market Cap
$506.13M
52 Week Low
$14.65
52 Week High
$37.27
P/E
-7.02x
P/B
2.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$98.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$83M
Beta
1.47
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NGNE Overview
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NGNE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important NGNE news, forecast changes, insider trades & much more!
NGNE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NGNE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NGNE ($32.03) is overvalued by 621.66% relative to our estimate of its Fair Value price of $4.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NGNE ($32.03) is not significantly undervalued (621.66%) relative to our estimate of its Fair Value price of $4.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NGNE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NGNE due diligence checks available for Premium users.
Valuation
NGNE fair value
Fair Value of NGNE stock based on Discounted Cash Flow (DCF)
Price
$32.03
Fair Value
$4.44
Overvalued by
621.66%
NGNE ($32.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NGNE ($32.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NGNE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NGNE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.02x
Industry
16.27x
Market
12.39x
NGNE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.13x
Industry
5.34x
NGNE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NGNE's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.9M
Profit Margin
0%
NGNE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$263.1M
Liabilities
$25.4M
Debt to equity
0.11
NGNE's short-term assets ($246.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NGNE's short-term assets ($246.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NGNE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NGNE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.1M
Investing
$46.2M
Financing
$195.0k
NGNE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NGNE vs Biotech Stocks
Neurogene Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.